Ultra long-acting β₂-agonists in development for asthma and chronic obstructive pulmonary disease

Author： Cazzola Mario Matera Maria Gabriella Lötvall Jan

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.14, Iss.7, 2005-07, pp. : 775-783

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Acting Agonists in the Management of Stable Chronic Obstructive Pulmonary Disease

By Cazzola M.

Drugs, Vol. 60, Iss. 2, 2000-08 ,pp. : 307-320

Adis International

Access to resources Recommend Favorite

A Benefit-Risk Assessment of Inhaled Long-Acting β 2 -Agonists in the Management of Obstructive Pulmonary Disease

By Sovani Milind P. Whale Christopher I. Tattersfield Anne. E.

Drug Safety, Vol. 27, Iss. 10, 2004-01 ,pp. : 689-715

Adis International

Access to resources Recommend Favorite

Indacaterol: a new long-acting β₂-agonist in the management of chronic obstructive pulmonary disease

By Steiropoulos Paschalis Papanas Nikolaos Nena Evangelia Bouros Demosthenes

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 1015-1029

Informa Healthcare

Access to resources Recommend Favorite

Combination Therapy of Inhaled Corticosteroids and Long-Acting &bgr;2- Adrenergics In Management of Patients with Chronic Obstructive Pulmonary Disease

Current Pharmaceutical Design, Vol. 10, Iss. 28, 2004-11 ,pp. : 3547-3560

Bentham Science Publishers

Access to resources Recommend Favorite

Long-acting β₂ agonists

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 1, 2006-01 ,pp. : 99-104

Informa Healthcare

Access to resources Recommend Favorite